COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY

被引：0
|
作者：
Di Costanzo, A. [1 ]
Uster, A. [2 ]
Vassallo, C. [1 ]
Fiorentino, F. [1 ]
机构：
[1] IQVIA Solut Srl, Milan, Italy
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE117
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Masahide Kondo
    Kunihiro Yamagata
    Shu-Ling Hoshi
    Chie Saito
    Koichi Asahi
    Toshiki Moriyama
    Kazuhiko Tsuruya
    Hideaki Yoshida
    Kunitoshi Iseki
    Tsuyoshi Watanabe
    Clinical and Experimental Nephrology, 2012, 16 : 279 - 291
  • [32] Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia
    Lim, Soo Kun
    Lee, Shaun Wen Huey
    PLOS ONE, 2024, 19 (03):
  • [33] Cost-Effectiveness of Kidney Transplantation From DCD in Italy
    Cavallo, M. G.
    Sepe, V.
    Conte, F.
    Abelli, M.
    Ticozzelli, E.
    Bottazzi, A.
    Geraci, P. M.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (10) : 3289 - 3296
  • [34] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    Cost Effectiveness and Resource Allocation, 19
  • [35] THE COST-EFFECTIVENESS OF SCREENING FOR MICROALBUMINURIA: A SIMULATION MODEL FOR CHRONIC KIDNEY DISEASE
    Hoerger, Thomas
    Witterborn, John
    Segel, Joel
    Burrows, Nilka Rios
    Eggers, Paul
    Pavkov, Meda
    Jordan, Regina
    Schoolwerth, Anton C.
    Willams, Desmond
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A42 - A42
  • [36] Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
    Schlackow, Iryna
    Kent, Seamus
    Herrington, William
    Emberson, Jonathan
    Haynes, Richard
    Reith, Christina
    Collins, Rory
    Landray, Martin J.
    Gray, Alastair
    Baigent, Colin
    Mihaylova, Borislava
    Baxter, A.
    Young, A.
    Hill, M.
    Knott, C.
    Cass, A.
    Feldt-Rasmussen, B.
    Fellstrom, B.
    Grobbee, D. E.
    Gronhagen-Riska, C.
    Haas, M.
    Holdaas, H.
    Hooi, L. S.
    Jiang, L.
    Kasiske, B.
    Krairittichai, U.
    Levin, A.
    Massy, Z. A.
    Tesar, V.
    Walker, R.
    Wanner, C.
    Wheeler, D. C.
    Wiecek, A.
    Dasgupta, T.
    Herrington, W.
    Lewis, D.
    Mafham, M.
    Majoni, W.
    Reith, C.
    Emberson, J.
    Parish, S.
    Simpson, D.
    Strony, J.
    Musliner, T.
    Agodoa, L.
    Armitage, J.
    Chen, Z.
    Craig, J.
    de Zeeuw, D.
    Gaziano, J. M.
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 170 - 179
  • [37] Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
    Rebecca L. Tisdale
    Marika M. Cusick
    Kelly Zhang Aluri
    Thomas J. Handley
    Alice Kate Cummings Joyner
    Joshua A. Salomon
    Glenn M. Chertow
    Jeremy D. Goldhaber-Fiebert
    Douglas K. Owens
    Journal of General Internal Medicine, 2022, 37 : 3380 - 3387
  • [38] Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait
    Swidan, Ahmed
    Elsisi, Gihan Hamdy
    Ibrahim, Mohamed M. M.
    Aljazzar, Mohammad
    Sallam, Hossameldin Tawfik
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 271 - 282
  • [39] Use of surrogacy for women with chronic kidney disease: a cost-effectiveness analysis
    Farwell, Jennifer
    Wyatt, Solange
    Rueda, Jose
    Emerson, Jenna
    Page, Jessica
    Fowler, Jessica
    Allen, Allison
    Caughey, Aaron
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S153 - S153
  • [40] COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC KIDNEY DISEASE
    Rosselli, D.
    DeAntonio, R.
    Calderon, C.
    Sanabria, M.
    VALUE IN HEALTH, 2009, 12 (03) : A200 - A200
12345